What evidence does a down-classification petition need to succeed?

A petition to move a device type from Class III to Class II must show that general and special controls, rather than premarket approval, are sufficient to provide reasonable assurance of safety and effectiveness for that entire generic device type. This typically draws on years of post-market surveillance data, MDR trends, published literature, and sometimes registry data showing the risk profile is well-characterized and manageable through labeling, performance standards, or design-specific special controls. Petitions built on a single company's product experience rather than the generic device type as a whole are weaker because reclassification applies to every device in that category, not just the petitioner's.

Why do reclassification petitions usually come from industry groups rather than single companies?

Because reclassification changes the regulatory burden for an entire generic device type, every competitor manufacturing that type of device benefits equally from a successful down-classification, not just the company that filed the petition. This free-rider dynamic means individual companies often have limited incentive to bear the cost of preparing a petition alone, so trade associations or industry consortia frequently coordinate and fund these efforts collectively.

Does a reclassification petition replace the need for a device-specific 510(k) or PMA?

No, reclassification changes what regulatory pathway applies to a device type going forward, but a manufacturer whose device is reclassified from Class III to Class II still needs to obtain marketing authorization for its specific device, typically through a 510(k) rather than a PMA, once the new classification and any special controls take effect. The petition itself does not authorize marketing of any individual product; it changes the rules that subsequent submissions must follow.

All terms

RegulatoryRegulated Pathways Global Markets

Device Reclassification Petition

Formal request to FDA to move a device type from one classification (I, II, or III) to another, either down-classifying or up-classifying.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

Definition

A reclassification petition is a formal submission asking FDA to change the regulatory classification of a generic type of device. Section 513(e) of the FD&C Act authorizes FDA-initiated reclassification; Section 513(f)(3) authorizes manufacturer-initiated petitions. Petitions must include valid scientific evidence showing that the device type warrants a different classification, typically that risks can be adequately controlled by general or special controls (down-classification from III to II) or that existing controls are insufficient (up-classification).

What the regulation says

Reclassification petitions are governed by the applicable FD&C Act classification authority and 21 CFR Part 860, including section 860.123. Include unfavorable evidence as well as support for the proposed class. Distinguish section 513(e) reclassification based on new information from section 513(f)(3) and from De Novo classification under section 513(f)(2).

What this means in practice

Reclassification is uncommon but strategically powerful. Down-classifying a Class III device type to Class II eliminates the PMA burden for the entire device class, affecting every competitor. FDA periodically reclassifies device types based on accumulated post-market evidence (e.g., reclassification of certain external defibrillators, some surgical staplers). Manufacturer-initiated petitions typically come from industry consortia rather than individual companies because the benefits accrue to all competitors.

Examples

Illustrative: A consortium of manufacturers filed a reclassification petition to move a certain type of implantable sensor from Class III to Class II, presenting evidence that standard performance testing and labeling controls are now sufficient to assure safety and effectiveness.
Illustrative: Following years of post-market surveillance data, the FDA initiated a reclassification of a specific type of diagnostic imaging software from Class I to Class II, requiring special controls due to newly identified risks related to data interpretation.
Illustrative: An industry group submitted a petition to down-classify a novel, non-invasive therapeutic device from Class III to Class II, demonstrating through clinical studies that its risks could be adequately mitigated by well-established special controls and robust post-market monitoring.

Common pitfalls

•Treating a reclassification petition as a substitute for a 510(k) or De Novo, petitions reclassify the entire generic type, not individual products.
•Underestimating the evidence bar, FDA requires comprehensive scientific evidence about the device type's risk profile across the market.
•Ignoring the public comment and Federal Register process, reclassifications go through formal rulemaking.

Frequently asked questions

Both can. Section 513(e) of the FD&C Act authorizes FDA to initiate reclassification on its own, typically based on accumulated post-market evidence about a generic device type, while Section 513(f)(3) authorizes a manufacturer or other interested party to petition FDA directly for a classification change. Manufacturer-initiated petitions are handled under 21 CFR 860.132 and FDA-initiated actions under 21 CFR 860.130, but both require valid scientific evidence supporting the requested change.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

510(k) Premarket Notification(510(k))

FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.

Regulatory

Class III Device

FDA's highest-risk device class, generally requiring PMA.

Regulatory

De Novo Classification Request(De Novo)

Pathway to classify novel low- to moderate-risk devices that lack a predicate.

Regulatory

General Controls

Baseline FDA requirements that apply to all medical devices regardless of class.

More in Regulatory

· Same category

Regulatory

Premarket Approval(PMA)

FDA's most stringent device marketing application, required for high-risk Class III devices.

Regulatory

Special Controls

Device-type-specific FDA requirements (often performance standards, labeling, or post-market surveillance) that apply on top of General Controls.

Regulatory

510(k) Summary vs 510(k) Statement

Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.

Regulatory

513(g) Request for Information(513(g))

Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (2)

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Official-source claim check: 2026-11-01

Reclassification petitions require device identification, requested action, reasons and supporting data, unfavorable evidence, and applicable new information under 21 CFR 860.123.

Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.

Remaining verification limits

Original merged record reviewed in full. Illustrative examples are hypothetical, not verified case histories. Evidence supports the specific propositions below, not an assertion that every linked page verifies all merged content.
Detailed procedural deadlines and all historical examples were not independently established from the retrieved petition-content regulation.

Tier 1Binding law and standards· 2Tier 2Regulator guidance and consensus· 1

Link health: 2 verified 1 unchecked· last checked 2026-06-20

FDA·1eCFR·1IMDRF·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Regulatory0 / 101

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Regulatory
Sources: 3
Updated: 6/20/2026

Compare with another term

Learn in 60 seconds

Formal request to FDA to move a device type from one classification (I, II, or III) to another, either down-classifying or up-classifying.

·Reclassification is uncommon but strategically powerful.
·Down-classifying a Class III device type to Class II eliminates the PMA burden for the entire device class, affecting every competitor.
·FDA periodically reclassifies device types based on accumulated post-market evidence (e.g., reclassification of certain external defibrillators, some surgical staplers).

Remember this

Watch out: Treating a reclassification petition as a substitute for a 510(k) or De Novo, petitions reclassify the entire generic type, not individual products.

Related terms

You may also need

Auto-suggested from Regulatory and shared keywords.

All Regulatory terms

From the Blue Goat network

Related resources and services on this topic.